Trinity Biotech plc
Trinity Biotech acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments. The company offers tests for infectious diseases, viral pathogens, diabetes monitoring, and autoimmune disorders. Products are sold through a direct sales force and independent distributors. Trinity Biotech also provides reagent products for liver and kidney disease diagnosis. The company serves public health authorities, NGOs, and clinical labs. It was incorporated in 1992 and is headquartered in Ireland.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (100.00) is significantly higher than the sector mean (13.90).
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (2.97%).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |